ALKERMES | ALKS - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
AbbVie USD 7.61B 2.04B 2026-06
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
ALKERMES USD -61.93M 122.3M 2026-03
Amgen USD 2.08B 570M 2026-03
Biogen USD 647.3M 269.6M 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 8.85B 583.8M 2026-03
Gilead Sciences USD -7.53B 10.11B 2026-06
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -114M 21M 2026-06
J&J USD 8.66B 839M 2026-06
Merck USD -3.53B 6.95B 2026-03
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Otsuka Holdings JPY 130.23B 54.96B 2026-03
Pfizer USD -653M 5.84B 2026-06
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Vertex Pharmaceuticals USD 1.39B 138.9M 2026-06